Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | RET D898_E901del |
Therapy | Cabozantinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET D898_E901del | Advanced Solid Tumor | resistant | Cabozantinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing RET D898_E901del were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 37535881). | 37535881 |
PubMed Id | Reference Title | Details |
---|---|---|
(37535881) | D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms. | Full reference... |